Codexis (NASDAQ:CDXS) spotted trading -19.90% off 52-week high price. On the other end, the stock has been noted 42.07% away from the low price over the last 52-weeks. The stock changed 3.06% to recent value of $18.01. The stock transacted 539556 shares during most recent day however it has an average volume of 309.61K shares. The company has 58.20M of outstanding shares and 56.37M shares were floated in the market.
On Jan. 10, 2020, Codexis (NASDAQ:CDXS) a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, have signed an agreement to advance a lead candidate discovered through a Strategic Collaboration Agreement (SCA) into preclinical development and early clinical studies. The SCA, signed in 2017, was an agreement to co-discover new enzyme therapy candidates for Nestlé Health Science’s nutritional therapies portfolio.
The companies’ new agreement will advance the development of CDX-7108, the lead candidate for a potential treatment of a GI disorder. In parallel, the original SCA will be extended through the end of 2021 to support the discovery of therapeutic candidates for additional disorders.
Our new and extended agreements with Codexis are a demonstration of the progress of the biotherapeutic pipeline as a result of our partnership, building on the previously established clinical success with CDX-6114 targeting phenylketonuria, said Greg Behar, CEO of Nestlé Health Science. The CDX-7108 program is the first project performed under the SCA, and in less than two years from conceptualization, we have created an orally-administrable enzyme candidate that meets our target criteria for advancement.
Its earnings per share (EPS) expected to touch remained 83.10% for this year while earning per share for the next 5-years is expected to reach at 15.00%. CDXS has a gross margin of 77.80% and an operating margin of -18.60% while its profit margin remained -17.90% for the last 12 months.
According to the most recent quarter its current ratio was 7.4 that represents company’s ability to meet its current financial obligations. The price moved ahead of 9.40% from the mean of 20 days, 15.58% from mean of 50 days SMA and performed 8.19% from mean of 200 days price. Company’s performance for the week was 9.12%, 14.89% for month and YTD performance remained 12.66%.